Literature DB >> 15808755

Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease.

Paul N Hopkins1, Lily L Wu, Steven C Hunt, Eliot A Brinton.   

Abstract

OBJECTIVES: This study was designed to explore contributions of plasma total triglycerides (TGs) and type III hyperlipidemia to the risk of premature familial coronary artery disease (CAD).
BACKGROUND: Although plasma TGs are recognized as a risk factor for CAD, the independence of this association from related risk factors remains controversial. Also, the degree of CAD risk conferred by excess remnants of TG-rich lipoproteins in type III hyperlipidemia remains unclear.
METHODS: We analyzed lipids by ultracentrifugation in a series of 653 cases with premature familial CAD (myocardial infarction or revascularization by age 55 years in men or age 65 years in women, with similar onset in at least one other first-degree relative) and in 1,029 control subjects. The relationship of CAD risk to various strata of plasma TGs, high-density lipoprotein (HDL) cholesterol, and type III hyperlipidemia, and interactions among these variables were examined by multiple logistic regression, adjusting for other CAD risk factors.
RESULTS: The odds ratio for CAD with elevated plasma TG rose progressively to 11.4 in those with TGs 500 to 799 mg/dl (95% confidence interval 3.4 to 38.0, p < 0.0001) compared with <100 mg/dl, even after correction for HDL cholesterol, other elements of the metabolic syndrome, and other CAD risk factors. Risk of CAD associated with type III hyperlipidemia (found in 3.4% of cases) was also markedly increased independent of other risk factors (odds ratios of 5 to 10 depending on the model, all with p < 0.002).
CONCLUSIONS: The association between the plasma TG level and premature familial CAD is strong, graded, and independent. Risk of CAD is also strikingly elevated with type III hyperlipidemia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15808755     DOI: 10.1016/j.jacc.2004.11.062

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  38 in total

1.  Dysbetalipoproteinemia: Two cases report and a diagnostic algorithm.

Authors:  Anastazia Kei; George Miltiadous; Eleni Bairaktari; Marilena Hadjivassiliou; Marios Cariolou; Moses Elisaf
Journal:  World J Clin Cases       Date:  2015-04-16       Impact factor: 1.337

Review 2.  Consensus statement on management of dyslipidemia in Indian subjects.

Authors:  K Sarat Chandra; Manish Bansal; Tiny Nair; S S Iyengar; Rajeev Gupta; Subhash C Manchanda; P P Mohanan; V Dayasagar Rao; C N Manjunath; J P S Sawhney; Nakul Sinha; A K Pancholia; Sundeep Mishra; Ravi R Kasliwal; Saumitra Kumar; Unni Krishnan; Sanjay Kalra; Anoop Misra; Usha Shrivastava; Seema Gulati
Journal:  Indian Heart J       Date:  2014-12-24

Review 3.  Treatment of hypertriglyceridemia.

Authors:  Warren H Capell; Robert H Eckel
Journal:  Curr Diab Rep       Date:  2006-06       Impact factor: 4.810

4.  Shorter telomere length in Europeans than in Africans due to polygenetic adaptation.

Authors:  Matthew E B Hansen; Steven C Hunt; Rivka C Stone; Kent Horvath; Utz Herbig; Alessia Ranciaro; Jibril Hirbo; William Beggs; Alexander P Reiner; James G Wilson; Masayuki Kimura; Immaculata De Vivo; Maxine M Chen; Jeremy D Kark; Daniel Levy; Thomas Nyambo; Sarah A Tishkoff; Abraham Aviv
Journal:  Hum Mol Genet       Date:  2016-03-02       Impact factor: 6.150

Review 5.  Hypertriglyceridemia-why, when and how should it be treated?

Authors:  I Gouni-Berthold; W Krone
Journal:  Z Kardiol       Date:  2005-11

6.  Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients.

Authors:  Vasilios G Athyros; Anna I Kakafika; Athanasios A Papageorgiou; Konstantinos Tziomalos; Athanasios Skaperdas; Efstathios Pagourelias; Athina Pirpasopoulou; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  Lipids       Date:  2007-08-23       Impact factor: 1.880

7.  Impaired coronary function in Wistar Ottawa Karlsburg W rats-a new model of the metabolic syndrome.

Authors:  Olaf Grisk; Tillmann Frauendorf; Torsten Schlüter; Ingrid Klöting; Beate Kuttler; Alexander Krebs; Jan Lüdemann; Rainer Rettig
Journal:  Pflugers Arch       Date:  2007-05-01       Impact factor: 3.657

8.  KCNQ1 gene polymorphisms are associated with lipid parameters in a Chinese Han population.

Authors:  Zhong Chen; Quanzhong Yin; Genshan Ma; Qi Qian
Journal:  Cardiovasc Diabetol       Date:  2010-08-11       Impact factor: 9.951

9.  Association of the level of heteroplasmy of the 15059G>A mutation in the MT-CYB mitochondrial gene with essential hypertension.

Authors:  Igor A Sobenin; Dimitry A Chistiakov; Margarita A Sazonova; Maria M Ivanova; Yuri V Bobryshev; Alexander N Orekhov; Anton Y Postnov
Journal:  World J Cardiol       Date:  2013-05-26

10.  Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.

Authors:  Peter H Jones; Harold E Bays; Michael H Davidson; Maureen T Kelly; Susan M Buttler; Carolyn M Setze; Darryl J Sleep; James C Stolzenbach
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.